CogNet Mammo
CogNet Mammo is a trustworthy and secure suite of AI products for improving breast cancer screening & women's health outcomes.
Essential Patents
MedCognetics' mammogram suite is built on two groundbreaking U.S. patents:
Racially Unbiased Deep Learning-Based Mammogram Analyzer, US 11,948,297 B1
Continuation Patent, US 12,243,232 B1
​
These patents reflect MedCognetics' ongoing commitment to creating fair, trustworthy, and generalizable AI.
Triage
Empower radiologists to act faster with AI-driven triage. CogNet AI-MT* and CogNet AI-MT+ provide triage for FFDM and DBT images, flagging suspicious cases & ensuring the most urgent mammograms are reviewed first.
Detection
See what others might miss. MedCognetics' detection engine uses advanced deep learning to highlight subtle cancer patterns, improving sensitivity without overwhelming radiologists with false alarms.
Density
Personalized screening starts with breast density. Our AI delivers consistent, accurate density classification, supporting risk-based screening decisions and compliance with reporting regulations.
Patient Risk Score
Move beyond snapshot—predict the future. MedCognetics' patient risk scoring uses advanced imaging biomarkers to estimate individualized breast cancer risk, enabling smarter, more personalized screening strategies.
Breast Arterial Calcifications
Go beyond cancer screening and analyze tissue for the presence of breast arterial calcifications, an indicator related to cardiovascular health.
FEATURE UNDER DEVELOPMENT
*Product is FDA cleared. Unless otherwise noted, features on this page are only deployable under IRB.
​
At the core of the mammo suite is CogNet AI-MT®, FDA-cleared for triage of mammogram images in the cloud. This software reduces disparities in cancer detection by delivering consistent performance across populations. Its next-generation enhancement incorporating DBT, CogNet AI-MT+, is currently under FDA review. All other mammogram suite products are in various stages of FDA submission, reflecting MedCognetics' commitment to rigorous regulatory pathways.